CALGARY, AB, July 2, 2020 /CNW/ - Nanalysis Scientific Corp.
("Nanalysis" or the "Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA:
1N1) is pleased to announce that the Board of Directors approved on
July 1, 2020 the granting of 40,000
restricted share units ("RSUs" ) to each director of the Company
pursuant to the Company's Restricted Share Unit Plan (the "RSU
Plan") for a total of 160,000 RSUs. These RSUs vest in two stages,
one-half 18 months from the date of grant and one-half 36 months
from the date of grant. Each vested RSU entitles the holder
to receive one common share of the Company (a "Common Share"). The
RSU Plan was approved by the disinterested shareholders of the
Company at the annual general and special meeting held on
June 23, 2020. The fixed maximum
number of the Company's Common Shares which may be available for
issuance upon settlement of the RSUs issued under the RSU Plan is
1,000,000 Common Shares. In accordance with the policies of
the TSX Venture Exchange, the maximum number of Common Shares which
may be reserved for issuance under the RSU Plan and the Company's
Stock Option Plan, in aggregate, cannot exceed 10% of the total
number of the Company's issued and outstanding Common
Shares.
About Nanalysis Scientific Corp.
(TSXV:NSCI, OTCQX:NSCIF,
FRA:1N1)
The Company trades on the TSX Venture Exchange (TSXV) in
Canada with ticker symbol 'NSCI'
and over the counter in the United
States under the ticker symbol 'NSCIF'. Nanalysis business
is what we term "MRI for industry": It develops and manufactures
portable Nuclear Magnetic Resonance (NMR) spectrometers or
analyzers for laboratory and industrial markets. The NMReady60™ was
the first fully featured portable NMR spectrometer in a single
compact enclosure requiring no liquid helium or any other cryogens,
and the company continues to develop new products and has a strong
innovation pipeline. Nanalysis began taking orders for the 100MHz
device in early 2020. The Company's new device will be the most
powerful non-cryogen, permanent magnet compact NMR device ever
brought to market. Nanalysis devices are used by chemical
professionals in many industries (oil and gas, chemical, mining,
pharma, biotech, flavor and fragrances, agrochemicals, and more) as
well as numerous government and university research labs around the
world. The company continues to exploit new global market
opportunities both independently and with partners. March 2020, the Company acquired all outstanding
shares of RS2D, a complementary technology company based in
Strasbourg France that specializes
in the development of cutting-edge MR electronics. Based on a
single electronic board, RS2D has developed MR product lines in
high-field ("HF") NMR and magnetic resonance imaging ("MRI") that
can further advance Nanalysis' existing product line, while the new
products to round out the Company's magnetic resonance technology
portfolio.
Notice regarding Forward Looking Statements and Legal
Disclaimer
This news release contains certain "forward-looking statements"
within the meaning of such statements under applicable securities
law. Forward-looking statements are frequently characterized by
words such as "anticipates", "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed", "positioned" and other similar
words, or statements that certain events or conditions "may" or
"will" occur. These statements are only predictions. Various
assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout
this news release. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation
Services Provider accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Nanalysis Scientific Corp.